The Potential Roles of Superoxide Dismutase, Matrix-Metalloprotinase-9 and Interlukine -18 with the Prevalence and Progression of Type II Diabetes Mellitus
American Journal of Internal Medicine
Volume 3, Issue 3, May 2015, Pages: 103-116
Received: Mar. 17, 2015; Accepted: Mar. 24, 2015; Published: Mar. 30, 2015
Views 2782      Downloads 181
Authors
Shwan Ali Umar, Ministry of Health, Zanco city, Erbil, Iraq
Shatha Rouf Moustafa, College of Pharmacy, Hawler Medical University, Havalan City, Erbil, Iraq
Article Tools
Follow on us
Abstract
Background and Objectives: Type II diabetes mellitus is becoming the most important health problems. It is important to find new pathogenic pathways to provide opportunities for early diagnosis and targets for novel treatments. Aims: to investigate the effect of type II diabetes mellitus on serum levels super oxide dismutase as a potential biomarkers of oxidant /antioxidant imbalance, matrix-metaloprotinase-9, and interlukine -18 as an inflammatory biomarkers and estimated their relationships with prevalence and progression of disease, to find out the effects of other confounding factors severity of disease, gender, and age on the serum interested parameters levels, finally detected the correlation coefficient between the studied parameters. Methods: This study was designed to examine the associations between the parameters with the prevalence and progression of disease in 50 patients, and an equal number of matched age –gender healthy adults were also enrolled in this study as a control group. The hypothesis of the study stated that oxidant /antioxidant imbalance and inflammatory process influence the risk of adverse clinical outcomes are worthy for investigating. To elucidate this hypothesis, the parameters were investigated using enzyme linked immunosorbent assay. Statistical Analyses: All analyses were performed with SPSS version 18. Results: Patients showed a significant variations in the serum focused parameters levels. The level of superoxide dismutase in patient and control groups were (301.684 ±97.041), (501.447 ±162.781) (ng/ml) respectively. The level of matrix–metalloprotinase-9 in patient and control groups were (2.632 ± 1.745), (1.506± 0.945) ng/ml respectively. The level of interlukine -18 in patients and control groups were (93.996 ±21.297), (48.400 ±26.375) (pg/ml) respectively. Conclusions: The prevalence of type II diabetes mellitus in the Erbil population constitutes a major health problem. Oxidative stress is increased in type II diabetes mellitus and this finding may explain the role of oxidant /antioxidants status imbalance leading to significant reduction in the serum superoxide dismutase level concomitant with increased inflammatory process leading to significant elevation of matrix- metaloptotinase-9 and interlukine -18, and these findings added a prognostic information to type II diabetes mellitus. Data demonstrated a highly significant association between the variation in the serum parameters levels with prevalence and progression of the disease. Accordingly, these parameters have been evaluated as potential tools for type II diabetes mellitus risk prediction. It can therefore be concluded that hyperglycemia influences the etiopathogenesis of type II diabetes mellitus.
Keywords
Diabetes Mellitus Type II, Superoxide dismutase, Matrixmetalloproteinase-9, Interlukine -18
To cite this article
Shwan Ali Umar, Shatha Rouf Moustafa, The Potential Roles of Superoxide Dismutase, Matrix-Metalloprotinase-9 and Interlukine -18 with the Prevalence and Progression of Type II Diabetes Mellitus, American Journal of Internal Medicine. Vol. 3, No. 3, 2015, pp. 103-116. doi: 10.11648/j.ajim.20150303.14
References
[1]
Bisht Shradha, Sisodia S. (2010). Diabetes, Dyslipidemia, Antioxidant and Status of Oxidative Stress. International Journal of Research in Ayurveda & Pharmacy, 1(1): 33-42 .
[2]
Bigagli E., Raimondi L., Mannucci E., Colombi C., Bardini G., Rotella C.M., Lodovici1 M. (2012). Lipid and protein oxidation products, antioxidant status and vascular complications in poorly controlled type 2 diabetes. The British Journal of Diabetes & Vascular Disease, 12: 33–39.
[3]
Simmi Kharb (2010). Activity of Extracellular Superoxide Dismutase in Gestational Diabetes. Research Journal of Obstetrics and Gynecology, 3: 1-4.
[4]
Dincer Y., Akcay T., Alademir Z., Ilkova H. (2002). Effect of oxidative stress on glutathione pathway in RBCs from patients with IDDM. Metabolism, 51: 1360– 1362.
[5]
Jansson SP., Andersson DK., Svardsudd K. (2007). Prevalence and incidence rate of diabetes mellitus in a Swedish community during 30 years of follow-up. Diabetologia, 50(4):703- 710.
[6]
Ceriello A. (2000). Oxidative stress and glycemic regulation. Metabolism, 49(2 Suppl 1):27–29.
[7]
Giacco F., Brownlee M. (2010). Oxidative stress and diabetic complications. Circ Res, 107:1058- 1070.
[8]
Hart PJ. (2006). Pathogenic superoxide dismutase structure, folding, aggregation and turnover. Curr Opin Chem Biol, 10:131-138.
[9]
Blancas-Flores, G., Almanza-Pérez, J.C., López-Roa, R.I., Alarcón-Aguilar, F.J., García-Macedo, R.,Cruz, M. (2010). Obesity as an inflammatory process. Bol. Med. Hosp. Infant. Mex, 67: 88-96.
[10]
Fernandez-Real JM, Ricart W. (2003). Insulin resistance and chronic cardiovascular inflammatory syndrome. Endocr Rev, 24: 278–301.
[11]
Krzysztof C. Lewandowski, Ewa Banach, Małgorzata Bieńkiewicz, and Andrzej Lewiński, (2011). Matrix metalloproteinases in type 2 diabetes and non-diabetic controls: effects of short-term and chronic hyperglycaemia. Arch Med Sci, 7(2): 294– 303.
[12]
Hopps Affiliations: Corresponding author at: Department of Internal and Specialistic Medicine, University of Palermo, Via del Vespro 129, 90127 Palermo, Italy. Tel.: + 39 91 655 4575; fax: + 39 91 655 4535/4319. E., Caimi G.(2012). Matrix metalloproteinases in metabolic syndrome. European Journal of Internal Medicine, 23 (2) : 99- 104.
[13]
Chung AW, Hsiang YN, Matzke LA, McManus BM, van Breemen C, Okon EB(2006). Reduced expression of vascular endothelial growth factor paralleled with the increased angiostatin expression resulting from the upregulated activities of matrix metalloproteinase-2 and -9 in human type 2 diabetic arterial vasculature. Circ Res, 99: 140–148.
[14]
Guillermo Zalba, Fortuño Ana, Díez Javier, ( 2006). Oxidative stress and atherosclerosis in early chronic kidney disease. Nephrol Dial Transplant, 21: 2686- 2690.
[15]
Kreisberg J.I., Garoni J.A., Radnik R., Ayo SH. (1994). High glucose and TGF_1 stimulate fibronectin gene expression through a cAMP response element.Kidney Int, 46: 1019– 1024.
[16]
Okamura H., Tsutsui H., Komatsu T., Yutsudo M., Hakura A., Tanimoto T., Torigoe K., Okura T., Nukada Y., Hattori K., Akita K., Namba M., Tanabe F., Konishi K., Fukuda S., Kurimoto M. (1995). Cloning of a new cytokine that induces IFN-gamma production by T cells. Nature, 378: 88–91.
[17]
Dai S.M., Matsuno H., Nakamura H., Nishioka K., Yudoh K. (2004). Interleukin-18 enhances monocyte tumor necrosis factor alpha and interleukin-1beta production induced by direct contact with T lymphocytes: implications in rheumatoid arthritis. Arthritis Rheum, 50 : 432 – 443.
[18]
Guler S., Cakir B., Demirbas B., Yonem A., Odabasi E., Onde U., Aykut O., Gursoy G. (2002). Plasma soluble intercellular adhesion molecule 1 levels are increased in type 2 diabetic patients with nephropathy. Horm Res, 58 : 67 –70.
[19]
Dinarello C. A., Fantuzzi G. (2003) . Interleukin-18 and host defense against infection. J. Infect. Dis, 187 : 370- 384 .
[20]
Van Guilder G.P., Hoetzer G.L., Greiner J.J., Stauffer B.L., Desouza C.A. (2006). Influence of metabolic syndrome on biomarkers of oxidative stress and inflammation in obese adults. Obesity Silver Spring, 14: 2127- 2131.
[21]
Esposito K., Nappo F., Marfella R., Giugliano G., Giugliano F., Ciotola M., Quagliaro L., Ceriello A., Giugliano D. (2002). Inflammatory cytokine concentrations are acutely increased by hyperglycemia in humans: role of oxidative stress. Circulation, 106: 2067– 2072.
[22]
Netea M.G. , Joosten L.A., Lewis E., Jensen D.R., Voshol P.J., Kullberg B.J., Tack C.J., van Krieken H., Kim S.H., Stalenhoef A.F., van de Loo F.A., Verschueren I., Pulawa L., Akira S., Eckel R.H., Dinarello C.A., van den Berg W., van der Meer J.W.(2006). Deficiency of interleukin-18 in mice leads to hyperphagia, obesity and insulin resistance. Nature medicine, 12(6): 650- 656.
[23]
Nakamura A., Shikata K., Hiramatsu M., Nakatou T., Kitamura T., Wada J., Itoshima T., Makino H. ( 2005). Serum interleukin-18 levels are associated with nephropathy and atherosclerosis in Japanese patients with type 2 diabetes. Diabetes Care, 28: 2890- 2895.
[24]
Aldebasi Y, Mohieldein A, Almansour Y, Almoteri B (2011). Imbalance of Oxidant/Antioxidant Status and Risk Factors for Saudi Type 2 Diabetic Patients with Retinopathy. Br J Medi Med Res, 1(4): 371- 384.
[25]
Lodovici M, Giovannelli L, Pitozzi V, Bigagli E, Bardini G, Rotella CM (2008). Oxidative DNA damage and plasma antioxidant capacity in type 2 diabetic patients with good and poor glycaemic control. Mutation Research, 638: 98–102.
[26]
Likidlilid A, Patchanans N, Peerapatdit T (2010). Lipid peroxidation and antioxidant enzyme activities in erythrocytes of type 2 diabetic patients. Journal of the Medical Association of Thailand, 93: 682– 693.
[27]
Hisalkar PJ, Patne AB , Fawade MM , Karnik AC (2012). Evaluation of plasma superoxide dismutase and glutathione peroxidase in type 2 diabetic patients. Biology and Medicine, 4 (2): 65-72.
[28]
Strain J.J.( 1991). Disturbances of micronutrient and antioxidant status in diabetes. Proceedings of the Nutrition Society, 50: 591– 504.
[29]
Uchimura K, Nagasaka A, Hayashi R, Makino M, Nagata M, Kakizawa H, Kobayashi T, Fujiwara K, Kato T, Iwase K,Shinohara R, Kato K and Itoh M (1999). Changes in superoxide dismutase activities and concentrations and myeloperoxidase activities in leukocytes from patients with diabetes mellitus. J. Diabet. Complications, 13: 264–270.
[30]
Gutteridge JM, Halliwell B (2000). Free radicals and antioxidant in the year 2000: a historical look to the future. In: Chuang ChinChiueh, ed. Reactive oxygen species from radiation to molecular biology. Annals of the New York Academy of Sciences, 899. New York: The New York Academy of Sciences:136–147.
[31]
Marjani et al ,(2010). Glycoxidative stress and cardiovascular complications in experimentally-induced diabetes: effects of antioxidant treatment. Open Cardiovasc Med J, 4: 240.
[32]
Ehsaneh Taheri Mahmoud Djalali , Ahmad Saedisomeolia , Ali Malekshahi Moghadam , Abolghasem Djazayeri and Mostafa Qorbani (2012). The relationship between the activates of antioxidant enzymes in red blood cells and body mass index in Iranian type 2 diabetes and healthy subjects. Journal of Diabetes & Metabolic Disorders, 11:3
[33]
Prakash S, Sudha S (2012). Lipid Peroxidation and Antioxidant Status in South Indian Patients with Type Diabetes Mellitus . IRJP, 3(3): 132- 134.
[34]
Sushma Verma, Nibha Sagar, Pushpank Vats, KN Shukla, Mohammad Abbas, Monisha Banerjee (2013). Antioxidant Enzyme Levels as Markers for Type 2 Diabetes Mellitus. International Journal of Bioassays, 2 (4) :685- 690.
[35]
Opara EC (2002). Oxidative stress, micronutrients, diabetes mellitus and its complications. J R Soc Health, 122(1):28– 34.
[36]
Badjatia N, Satyam A, Singh P, Seth A, Sharma A. (2009). Altered antioxidant status and lipid peroxidation in Indian patients with urothelial bladder carcinoma. J Urol Oncol, 28:1-8.
[37]
Taniguchi N.(1992). Clinical significance of superoxide dismutases:changes in aging, diabetes, ischemia and cancer. Adv Clin Chem, 29: 1-59.
[38]
Bray RC, Cockle SA, Fielden EM, Roberts PB, Rotilio G, Calabrese L. (1974) . Reduction and inactivation of superoxide dismutase by hydrogen peroxide. Biochem J, 139: 43-48.
[39]
Fajans S (1995). Diabetes mellitus, definition, classification, tests. In: Endocrinology Degroat L, 3rd ed, Saunders Co, USA, :1411- 1422.
[40]
MOUSSA S.A. (2008). Oxidative Stress in Diabetes Mellitus.Romanian J.Biophys, 18 (3) : 225– 236.
[41]
McLennan S.V., WangX.Y., Moreno V., Yue D.K. and TwiggS.M.(2004). Connective Tissue Growth Factor Mediates High Glucose Effects on Matrix Degradation through Tissue Inhibitor of Matrix Metalloproteinase Type 1: Implications for Diabetic Nephropathy. Endocrinology, 145 ( 12): 5646- 5655.
[42]
Kowluru RA (2010). Role of matrix metalloproteinase-9 in the development of diabetic retinopathy and its regulation by H-Ras. Invest Ophthalmol Vis Sci, 51:4320– 4326.
[43]
Jieli Chen, Alex Zacharek, Yisheng Cui , Cynthia Roberts, ;Michael Chopp (2011). White Matter Damage and the Effect of Matrix Metalloproteinases in Type 2 Diabetic Mice After Stroke. Stroke, ; 42: 445- 52.
[44]
Kowluru RA, Mohammad G, dos Santos JM, Zhong Q (2011). Abrogation of MMP-9 gene protects against the development of retinopathy in diabetic mice by preventing mitochondrial damage. Diabetes, 60:3023– 3033.
[45]
Mohammad G, Kowluru RA (2012) .Diabetic retinopathy and signaling mechanism for activation of matrix metalloproteinase-9. J Cell Physiol, 227: 1052– 1061.
[46]
Karhaiya Singh ,Neeraj K.Agrawal , Sanjeerv K.Gupta, Kiram Singh (2013).A Functional Single Nucleotide Polymorphism-1562C > Tin the Matrix Metalloproteinase Promotor Is Associated With Type2 Diabetes an Diabetic Foot Ulcer.Internation Journal of Lower Extremely Wounds, 12(3) :199-104.
[47]
Wen-Chung Tsai , Fang-Chen Liang,, Ju-Wen Cheng,, Li-Ping Lin, Shih-Chieh Chang, Hsiang-Hung Chen and Jong-Hwei S Pang (2013). High glucose concentration up-regulates the expression of matrix metalloproteinase-9 and -13 in tendon cells. BMC Musculoskeletal Disorders, 14: 255
[48]
Qing Zhong and Renu A. Kowluru (2013). Regulation of Matrix Metalloproteinase-9 by Epigenetic Modifications and the Development of Diabetic Retinopathy. Diabetes, 62 (7) 2559- 2568.
[49]
Sourav Kundu , Sathnur B. Pushpakumar , Aaron Tyagi , Denise Coley , Utpal Sen (2013). Hydrogen sulfide deficiency and diabetic renal remodeling: role of matrix metalloproteinase-9.American Journal of Physiology - Endocrinology and Metabolism, 304 : 1365- 1378.
[50]
Chung AW, Hsiang YN, Matzke LA, McManus BM, van Breemen C, Okon EB (2006). Reduced expression of vascular endothelial growth factor paralleled with the increased angiostatin expression resulting from the upregulated activities of matrix metalloproteinase-2 and -9 in human type 2 diabetic arterial vasculature. Circ Res, 99: 140–148.
[51]
Uemura S, Matsushita H, Li W, Glassford AJ, Asagami T, Lee KH (2001). Diabetes mellitus enhances vascular matrix metalloproteinase activity: role of oxidative stress. Circ Res, 88: 1291- 1298.
[52]
Vera Portik-Dobos , Mark P. Anstadt ,Jimmie Hutchinson , Mary Bannan and Adviye Ergul (2002). Evidence for a Matrix Metalloproteinase Induction/Activation System in Arterial Vasculature and Decreased Synthesis and Activity in Diabetes. Diabetes, 51(10): 3063- 3068.
[53]
Mike Sampson, Isabel Davies, Jelena Gavrilovic, Brendan Sussams , Jackie Brown, Sian Astley and David A Hughes (2004). Plasma matrix metalloproteinases, low density lipoprotein oxidisability and soluble adhesion molecules after a glucose load in type 2 diabetes. Cardiovasc Diabetol, 3:7–14.
[54]
Krzysztof C. Lewandowski, Ewa Banach, Małgorzata Bieńkiewicz, and Andrzej Lewiński (2011). Matrix metalloproteinases in type 2 diabetes and non-diabetic controls: effects of short-term and chronic hyperglycaemia. Arch Med Sci, 7(2): 294– 303.
[55]
Papazafiropoulou A , Perrea D, Moyssakis I, Kokkinos A, Katsilambros N, Tentolouris N (2010). Plasma levels of MMP-2, MMP-9 and TIMP-1 are not associated with arterial stiffness in subjects with type 2 diabetes mellitus. J Diabetes Complications, 24(1):20-27.
[56]
Pradhan A (2007). Obesity, metalic syndrome, and type 2 diabetes: inflammatory basis of glucose metabolic disorders. Nutr Rev, 65: 152- 156.
[57]
Pradhan AD, Cook NR, Buring JE (2003). C-reactive protein is independently associated with fasting insulin in non diabetic women.Arterioscler Thromb Vas Biol, 23 (4): 650- 655.
[58]
Thorand B, Kolb H, Baumert J, Koenig W, Chambless L, Meisinger C, Ilig T, Martin S, Herder C (2005). Elevated levels of interleukin-18 predict the development of type 2 diabetes: results from the MONICA/KORA Augsburg study 1984–2002. Diabetes, 54: 2932– 2938.
[59]
Netea MG , Joosten LA, Lewis E, Jensen DR, Voshol PJ, Kullberg BJ, Tack CJ, van Krieken H, Kim SH, Stalenhoef AF, van de Loo FA, Verschueren I, Pulawa L, Akira S, Eckel RH, Dinarello CA, van den Berg W, van der Meer JW.(2006). Deficiency of interleukin-18 in mice leads to hyperphagia, obesity and insulin resistance. Nature medicine, 12(6):650- 656.
[60]
Araki S, Haneda M, Koya D, Sugimoto T, Isshiki K, Chin-Kanasaki M, Uzu T, Kashiwagi A (2007). Predictive impact of elevated serum level of IL-18 for early renal dysfunction in type 2 diabetes: an observational follow-up study. Diabetologia, 50:867- 873.
[61]
Juliet Evans, Malcolm Collins, Courtney Jennings, Lize van der Merwe , Ingegerd Söderström , Tommy Olsson , Naomi S Levitt1, Estelle V Lambert and Julia H Goedecke (2007) . The association of interleukin-18 genotype and serum levels with metabolic risk factors for cardiovascular disease. Eur J Endocrinol, 157: 633 - 640.
[62]
Zilverschoon GR, Tack CJ, Joosten LA, Kullberg BJ, Meer JW, Netea MG (2008). Interleukin-18 resistance in patients with obesity and type 2 diabetes mellitus. Int J Obes (Lond), 32:1407- 1414.
[63]
Hivert MF, Sun Q, Shrader P, Mantzoros CS, Meigs JB, Hu FB (2009). Circulating IL-18 and the risk of type 2 diabetes in women. Diabetologia, 52: 2101- 2108.
[64]
Jagannathan, M., McDonnell, M., Liang, Y., Hasturk, H., Hetzel, J., Rubin, D., Kantarci, A., Van Dyke, T.E., Ganley-Leal, L.M., Nikolajczyk, B.S., (2010). Toll-like receptors regulate B cell cytokine production in patients with diabetes. Diabetologia, 53: 1461– 1471.
[65]
Arnalich F, Hernanz A, Lopez-Maderuelo D, Pena JM, Camacho J, Madero R, Vazquez JJ, Montiel C (2000). Enhanced acute-phase response and oxidative stress in older adults with type II diabetes. Horm Metab Res, 32 : 407 – 412.
[66]
Hung J, McQuillan BM, Chapman CM, Thompson PL, Beilby JP (2005). Elevated interleukin-18 levels are associated with the metabolic syndrome independent of obesity and insulin resistance. Arterioscler Thromb Vasc Biol, 25:1268– 1273.
[67]
Meneilly GS, Tessier D (2001). Diabetes in elderly adults. J Gerontol A Biol Sci Med Sci, 56: 5-13.
[68]
Molham Al-Habori,Mohamed Al-Mamari , Ali Al-Meeri (2004). Type II Diabetes Mellitus and impaired glucose tolerance in Yemen: prevalence, associated metabolic changes and risk factors. Diabetes Research and Clinical Practice, 65 (3) : 275– 281.
[69]
Undurti N. Das (2008). Risk of type 2 diabetes mellitus in those with hypertension. Eur Heart J, 29 (7): 952- 953.
[70]
Hamilton CA, Brosnan MJ, McIntyre M,Graham D, Dominiczak AF.(2001). Superoxide excess in hypertension and aging: a common cause of endothelial dysfunction. Hypertension, 37:529-534. (2 part 2).
[71]
Neil, H. A., Gatling, W., Mather, H. M., Thompson A.V. , Thorogood M. , Fowler G.H. , Hill R.D. and Mann J.I. (1987). The Oxford Community Diabetes Study: evidence for an increase in the prevalence of known diabetes in Great Britain. Diabetic Medicine, 4 (6) : 539–543.
[72]
Ruiz C, Alegria A, Barbera R, Farre R and Lagrda MJ (1999). Lipid peroxidation and antioxidant enzymes activities in patients with type I diabetes mellitus. Scand J Clin Lab Invest, 59: 99- 105.
ADDRESS
Science Publishing Group
1 Rockefeller Plaza,
10th and 11th Floors,
New York, NY 10020
U.S.A.
Tel: (001)347-983-5186